Translational Therapy Shared Resource Summary Transitioning sophisticated laboratory assays and the manufacturing of biotherapeutic products to the clinic often represents a significant hurdle for translation of laboratory studies to patient care. The purpose of the Translational Therapy Shared Resource (TTSR) is to provide state-of-the-art translational research support services to Masonic Cancer Center (MCC) members to facilitate the monitoring of clinical trials and the development of novel cellular and immune-based therapies. TTSR works directly with members of the Scientific Programs at the preclinical, clinical, and laboratory levels, with the goal of developing clinical trials to test novel therapies. It does this through the following specific aims: 1) To provide immune monitoring and biorepository management for clinical studies and trials, 2) To provide a cGMP-compliant facility to manufacture therapeutic biological products, and 3) To develop novel cellular and immune-based therapies. TTSR has 2 major components: the Translational Therapy Laboratory (TTL) and Molecular and Cellular Therapeutics (MCT). TTL provides immune monitoring and biorepository management; it is the central laboratory that processes research blood samples from patients enrolled in clinical trials. MCT is a cGMP- compliant production facility. TTSR collaborates with investigators in the Immunology and Transplant and Cellular Therapy Programs to first procure, select, and manipulate cellular products in the basic or preclinical research setting and then in large-scale preclinical validation runs leading to the production of these products in the GMP facility. Once trials begin, TTL processes samples from the trials and provides biologic correlates of how the products created by the MCT facility are performing. TTSR also collaborates with the Clinical Informatics Shared Resource and the Cancer Research Translational Initiative to assist investigators in correlating clinical outcomes with product characteristics and any alterations in host immune function. Martin Felices, PhD, Associate Professor of Medicine (Immunology Program), and John Wager, MD, Professor of Pediatrics (Transplant and Cellular Therapy Program [TCT]) co-lead TTSR and are supported by David McKenna, MD, Medical Director of MCT (TCT), and Rose Wangen, Coordinator of TTL. In fiscal year 2022, 38 people used TTSR, including 33 MCC members.